Details of the Drug

General Information of Drug (ID: DMMX2E6)

Drug Name
Pemetrexed
Synonyms
Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
Indication
Disease Entry ICD 11 Status REF
Malignant pleural mesothelioma 2C26.0 Approved [1], [2], [3], [4], [5]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 427.4
Topological Polar Surface Area (xlogp) 0.2
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 6
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [6]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.3 mL/min/kg [7]
Elimination
80% of drug is excreted from urine in the unchanged form [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.5 hours [7]
Metabolism
The drug is metabolized via the cytochrome P450 Enzymes [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.377 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.19% [7]
Vd
The volume of distribution (Vd) of drug is 16.1 L [10]
Water Solubility
The ability of drug to dissolve in water is measured as 90 mg/mL [6]
Chemical Identifiers
Formula
C20H21N5O6
IUPAC Name
(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
Canonical SMILES
C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
InChI
InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
InChIKey
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
Cross-matching ID
PubChem CID
135410875
ChEBI ID
CHEBI:63616
CAS Number
137281-23-3
DrugBank ID
DB00642
TTD ID
D0Y4GO
VARIDT ID
DR00318

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Thymidylate synthase (Candi TMP1) TTU6BFZ TYSY_CANAL Inhibitor [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Folate transporter 1 (SLC19A1) DTOSN46 S19A1_HUMAN Substrate [12]
Proton-coupled folate transporter (SLC46A1) DTDJEMI PCFT_HUMAN Substrate [13]
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [14]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [15]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [16]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Pemetrexed (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Framycetin DMF8DNE Moderate Decreased renal excretion of Pemetrexed caused by Framycetin mediated nephrotoxicity. Alcoholic liver disease [DB94] [69]
Inotersen DMJ93CT Moderate Decreased renal excretion of Pemetrexed caused by Inotersen mediated nephrotoxicity. Amyloidosis [5D00] [69]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Pemetrexed and Roflumilast. Asthma [CA23] [70]
Kanamycin DM2DMPO Moderate Decreased renal excretion of Pemetrexed caused by Kanamycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [69]
Streptomycin DME1LQN Moderate Decreased renal excretion of Pemetrexed caused by Streptomycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [69]
Gentamicin DMKINJO Moderate Decreased renal excretion of Pemetrexed caused by Gentamicin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [69]
Netilmicin DMRD1QK Moderate Decreased renal excretion of Pemetrexed caused by Netilmicin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [69]
Tobramycin DMUI0CH Moderate Decreased renal excretion of Pemetrexed caused by Tobramycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [69]
Etidronic acid DM1XHYJ Moderate Decreased renal excretion of Pemetrexed caused by Etidronic acid mediated nephrotoxicity. Bone paget disease [FB85] [69]
Methoxyflurane DML0RAE Moderate Decreased renal excretion of Pemetrexed caused by Methoxyflurane mediated nephrotoxicity. Corneal disease [9A76-9A78] [69]
Pentamidine DMHZJCG Moderate Decreased renal excretion of Pemetrexed caused by Pentamidine mediated nephrotoxicity. Fungal infection [1F29-1F2F] [69]
Amphotericin B DMTAJQE Moderate Decreased renal excretion of Pemetrexed caused by Amphotericin B mediated nephrotoxicity. Fungal infection [1F29-1F2F] [69]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Pemetrexed and Teriflunomide. Hyper-lipoproteinaemia [5C80] [71]
Givosiran DM5PFIJ Moderate Decreased renal excretion of Pemetrexed caused by Givosiran mediated nephrotoxicity. Inborn porphyrin/heme metabolism error [5C58] [69]
Balsalazide DMO091F Moderate Decreased renal excretion of Pemetrexed caused by Balsalazide mediated nephrotoxicity. Indeterminate colitis [DD72] [69]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Pemetrexed and Denosumab. Low bone mass disorder [FB83] [72]
Moxetumomab pasudotox DMN63DZ Moderate Decreased renal excretion of Pemetrexed caused by Moxetumomab pasudotox mediated nephrotoxicity. Mature B-cell leukaemia [2A82] [69]
Exjade DMHPRWG Moderate Decreased renal excretion of Pemetrexed caused by Exjade mediated nephrotoxicity. Mineral absorption/transport disorder [5C64] [69]
Gallium nitrate DMF9O6B Moderate Decreased renal excretion of Pemetrexed caused by Gallium nitrate mediated nephrotoxicity. Mineral excesses [5B91] [69]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Pemetrexed and Thalidomide. Multiple myeloma [2A83] [73]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Pemetrexed and Tecfidera. Multiple sclerosis [8A40] [74]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Pemetrexed and Siponimod. Multiple sclerosis [8A40] [75]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Pemetrexed and Fingolimod. Multiple sclerosis [8A40] [76]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Pemetrexed and Ocrelizumab. Multiple sclerosis [8A40] [77]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Pemetrexed and Ozanimod. Multiple sclerosis [8A40] [70]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Pemetrexed and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [78]
Temsirolimus DMS104F Moderate Decreased renal excretion of Pemetrexed caused by Temsirolimus mediated nephrotoxicity. Renal cell carcinoma [2C90] [69]
Colistimethate DMZ9BMU Moderate Decreased renal excretion of Pemetrexed caused by Colistimethate mediated nephrotoxicity. Respiratory infection [CA07-CA4Z] [69]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Pemetrexed and Canakinumab. Rheumatoid arthritis [FA20] [79]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Pemetrexed and Rilonacept. Rheumatoid arthritis [FA20] [79]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Pemetrexed and Golimumab. Rheumatoid arthritis [FA20] [80]
Sulfasalazine DMICA9H Moderate Decreased renal excretion of Pemetrexed caused by Sulfasalazine mediated nephrotoxicity. Rheumatoid arthritis [FA20] [69]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Pemetrexed and Leflunomide. Rheumatoid arthritis [FA20] [71]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Pemetrexed when combined with Anthrax vaccine. Sepsis [1G40-1G41] [81]
Telavancin DM58VQX Moderate Decreased renal excretion of Pemetrexed caused by Telavancin mediated nephrotoxicity. Staphylococcal/streptococcal disease [1B5Y] [69]
Sirolimus DMGW1ID Moderate Decreased renal excretion of Pemetrexed caused by Sirolimus mediated nephrotoxicity. Transplant rejection [NE84] [69]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Pemetrexed and Azathioprine. Transplant rejection [NE84] [75]
Tacrolimus DMZ7XNQ Moderate Decreased renal excretion of Pemetrexed caused by Tacrolimus mediated nephrotoxicity. Transplant rejection [NE84] [69]
Olsalazine DMZW9HA Moderate Decreased renal excretion of Pemetrexed caused by Olsalazine mediated nephrotoxicity. Ulcerative colitis [DD71] [69]
Plazomicin DMKMBES Moderate Decreased renal excretion of Pemetrexed caused by Plazomicin mediated nephrotoxicity. Urinary tract infection [GC08] [69]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Pemetrexed and Ganciclovir. Virus infection [1A24-1D9Z] [75]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Pemetrexed and Valganciclovir. Virus infection [1A24-1D9Z] [75]
⏷ Show the Full List of 42 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6837).
2 Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. 2009 Nov;66(2):141-9.
3 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
4 Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011 Oct;74(1):132-8.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 BDDCS applied to over 900 drugs
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
11 Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
12 Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
13 The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol. 2008 Sep;74(3):854-62.
14 Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
15 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
16 Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol. 2012 Feb;81(2):134-42.
17 pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos. 2011 Sep;39(9):1478-85.
18 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
19 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
20 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
21 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
22 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
23 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
24 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
25 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
26 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
27 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
28 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
29 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
30 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
31 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
32 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
33 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
34 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
35 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
36 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
37 The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
38 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
39 Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
40 Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014 Dec 13;3:732.
41 Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev. 2005;37(1):253-78.
42 Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
43 Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004.
44 Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14.
45 The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000 Sep 29;275(39):30069-74.
46 Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
47 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
48 Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
49 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
50 Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
51 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
52 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
53 Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
54 Drug Interactions in Infectious Diseases.
55 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
56 Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.
57 Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2009 Jul;61(7):911-8.
58 Characterization of uptake of folates by rat and human blood-brain barrier endothelial cells. Biofactors. 2010 May-Jun;36(3):201-9.
59 The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
60 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
61 Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
62 UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
63 DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
64 Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
65 Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44.
66 Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
67 A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
68 Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
69 Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
70 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
71 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
72 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
73 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
74 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
75 Cerner Multum, Inc. "Australian Product Information.".
76 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
77 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
78 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
79 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
80 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
81 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]